Bridgeway Capital Management LLC Lowers Position in Protara Therapeutics, Inc. (NASDAQ:TARA)

Bridgeway Capital Management LLC decreased its position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) by 49.2% during the fourth quarter, HoldingsChannel reports. The firm owned 25,000 shares of the company’s stock after selling 24,200 shares during the period. Bridgeway Capital Management LLC’s holdings in Protara Therapeutics were worth $132,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in TARA. Adage Capital Partners GP L.L.C. purchased a new stake in Protara Therapeutics during the fourth quarter valued at about $11,880,000. Blackstone Inc. purchased a new stake in Protara Therapeutics during the fourth quarter valued at about $8,870,000. RA Capital Management L.P. raised its position in Protara Therapeutics by 78.9% during the fourth quarter. RA Capital Management L.P. now owns 3,400,000 shares of the company’s stock valued at $17,952,000 after purchasing an additional 1,500,000 shares in the last quarter. Acorn Capital Advisors LLC purchased a new stake in Protara Therapeutics during the fourth quarter valued at about $6,757,000. Finally, 5AM Venture Management LLC purchased a new stake in Protara Therapeutics during the fourth quarter valued at about $4,224,000. Hedge funds and other institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Price Performance

NASDAQ TARA opened at $3.22 on Wednesday. The stock has a market capitalization of $124.22 million, a PE ratio of -1.14 and a beta of 1.73. Protara Therapeutics, Inc. has a 1 year low of $1.60 and a 1 year high of $10.48. The business’s 50-day moving average is $3.98 and its 200 day moving average is $4.12.

Protara Therapeutics (NASDAQ:TARA) last posted its earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.18. As a group, equities research analysts anticipate that Protara Therapeutics, Inc. will post -3.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $23.00 price objective on shares of Protara Therapeutics in a report on Monday, April 28th. Scotiabank assumed coverage on Protara Therapeutics in a report on Wednesday, April 16th. They issued a “sector outperform” rating and a $12.00 price objective on the stock. Cantor Fitzgerald assumed coverage on Protara Therapeutics in a report on Friday, March 14th. They issued an “overweight” rating on the stock. Finally, Lifesci Capital assumed coverage on Protara Therapeutics in a report on Tuesday, March 11th. They issued an “outperform” rating and a $22.00 price objective on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $20.40.

Insider Buying and Selling

In related news, insider Jacqueline Zummo sold 21,224 shares of the firm’s stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total value of $96,144.72. Following the sale, the insider now directly owns 98,861 shares of the company’s stock, valued at $447,840.33. This trade represents a 17.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 8.40% of the stock is owned by insiders.

Protara Therapeutics Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.